Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Ye, Wei Liang ^a   Du, Jiang Bo ^a   Zhang, Bang Le ^a   Na, Ren ^a   Song, Yan Feng ^a   Mei, Qi Bing ^a   Zhao, Ming Gao ^a   Zhou, Si Yuan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FOLIC ACID; MACROGOL; NANOPARTICLE; ANTINEOPLASTIC AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; POLY(ETHYLENE GLYCOL)-FOLATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TISSUE; CARDIOTOXICITY; CELL NUCLEUS; CELL TRANSPORT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; DRUG SYNTHESIS; FEMALE; GENE TRANSLOCATION; HEART; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LIFE EXTENSION; LYSOSOME; MOUSE; NEOPLASM; NONHUMAN; PH; SURVIVAL RATE; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; KB CELL LINE; NUDE MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; FOLIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; KB CELLS; MICE; MICE, NUDE; NANOPARTICLES; POLYETHYLENE GLYCOLS; SURVIVAL RATE;

EID: 84901365917     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097358     Document Type: Article

References (45)

1. Minko T, Kopeckova P, Pozharov V, Kopecek J (1998) HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release 54: 223-33. (Pubitemid 28342701)
2. Colin DVA, Dubernet C, Nemati F, Poupon MF, Puisieux F, et al. (1994) Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother Pharmacol 33: 504-08. (Pubitemid 24082346)
3. Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov 2: 347-60.
4. Maeda H, Matsumura Y (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 6: 193-210. (Pubitemid 20065994)
5. Fang J, Nakamura H, Maeda H (2011) The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63: 136-51.
6. Maeda H (2012) Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci 88: 53-71.
7. Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63: 131-35.
8. Cho K, Wang X, Nie S, Chen ZG, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14: 1310-16. (Pubitemid 351413909)
9. Lee ES, Na K, Bae YH (2005) Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 103: 405-18. (Pubitemid 40342538)
10. Sahoo SK, Labhasetwar V (2005) Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2: 373-83. (Pubitemid 41503678)
11. Barenholz Y (2012) Doxil® - the first FDA-approved nano-drug: lessons learned. J Control Release 10;160(2):117-34.
12. Koyama J, Honjo S, Morizono R, Goto T, Morita K, et al. (2011) Hepatocellular carcinoma with multiple lung metastasis resulting in long-term disease-free survival by transcatheter arterial infusion chemotherapy of SMANCS. Gan To Kagaku Ryoho 38(3):461-4.
13. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, et al. (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2: 751-60. (Pubitemid 350223348)
14. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, et al. (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338: 284-93. (Pubitemid 40312593)
15. Low PS, Antony AC (2004) Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev 56: 1055-58. (Pubitemid 38496506)
16. Dhawan D, Ramos-Vara JA, Naughton JF, Cheng L, Low PS, et al. (2013) Targeting folate receptors to treat invasive urinary bladder cancer. Cancer Res 73: 875-84.
17. Dosio F, Milla P, Cattel L (2010) EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs 11: 1424-33.
18. Ye WL, Teng ZH, Liu DZ, Cui H, Liu M, et al. (2013) Synthesis of a new pH-sensitive folate-doxorubicin conjugate and its antitumor activity in vitro. J Pharm Sci 102(2):530-40.
19. Filpula D, Zhao H (2008) Releasable PEGylation of proteins with customized linkers. Adv Drug Deliv Rev 60: 29-49. (Pubitemid 350181165)
20. Huan M, Zhang B, Teng Z, Cui H, Wang J, et al. (2012) In vitro and in vivo antitumor activity of a novel pH-activated polymeric drug delivery system for doxorubicin. PLoS One 7:e44116.
21. Huang L, Liu Y (2011) In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 13: 507-30.
22. Prabaharan M, Grailer JJ, Pilla S, Steeber DA, Gong S (2009) Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery. Biomaterials 30: 6065-75.
23. Yoo HS, Park TG (2004) Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release 100: 247-56. (Pubitemid 39491276)
24. Kim SH, Jeong JH, Joe CO, Park TG (2005) Folate receptor mediated intracellular protein delivery using PLL-PEG-FOL conjugate. J Control Release 103: 625-34. (Pubitemid 40471020)
25. Ghaghada KB, Saul J, Natarajan JV, Bellamkonda RV, Annapragada AV (2005) Folate targeting of drug carriers: a mathematical model. J Control Release 104: 113-28. (Pubitemid 40615240)
26. Liu F, Deng D, Chen X, Qian Z, Achilefu S, et al. (2010) Folate-polyethylene glycol conjugated near-infrared fluorescence probe with high targeting affinity and sensitivity for in vivo early tumor diagnosis. Mol Imaging Biol 12: 595-607.
27. Lancon A, Delmas D, Osman H, Thenot JP, Jannin B, et al. (2004) Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun 316: 1132-37. (Pubitemid 38369070)
28. Lancon A, Hanet N, Jannin B, Delmas D, Heydel JM, et al. (2007) Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab Dispos 35: 699-703. (Pubitemid 46641555)
29. Arote RB, Hwang SK, Lim HT, Kim TH, Jere D, et al. (2010) The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model. Biomaterials 31(8):2435-45.
30. van Steenis JH, van Maarseveen EM, Verbaan FJ, Verrijk R, Crommelin DJ, et al. (2003) Preparation and characterization of folate-targeted PEG-coated pDMAEMA-based polyplexes. J Control Release 87(1-3):167-76. (Pubitemid 36255454)
31. Andersson L, Davies J, Duncan R, Ferruti P, Ford J, et al. (2005) Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates. Biomacromolecules 6(2):914-26. (Pubitemid 40467837)
32. Leamon CP, Low PS (1991) Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A 88: 5572-76. (Pubitemid 21914787)
33. Hu Q, Gao X, Gu G, Kang T, Tu Y, et al. (2013) Glioma therapy using tumor homing and penetrating peptide-functionalized PEG-PLA nanoparticles loaded with paclitaxel. Biomaterials 34: 5640-50.
34. Xiong XB, Ma Z, Lai R, Lavasanifar A (2010) The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials 31: 757-68.
35. Jayant S, Khandare JJ, Wang Y, Singh AP, Vorsa N, et al. (2007) pH-triggered intracellular release from actively targeting polymer micelles. Pharm Res 24(11):2120-30.
36. Ma R, Yang H, Li Z, Liu G, Sun X, et al. (2012) Phenylboronic acid-based complex micelles with enhanced glucose-responsiveness at physiological pH by complexation with glycopolymer. Biomacromolecules 13(10):3409-17.
37. He C, Hu Y, Yin L, Tang C, Yin C (2010) Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31: 3657-66.
38. Yang C, Attia AB, Tan JP, Ke X, Gao S, et al. (2012) The role of non-covalent interactions in anticancer drug loading and kinetic stability of polymeric micelles. Biomaterials 33: 2971-79.
39. Torchilin VP (2007) Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 24: 1-16.
40. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5: 505-15.
41. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE (2009) Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 61(6):428-37.
42. Lalatsa A, Schatzlein AG, Mazza M, Le TB, Uchegbu IF (2012) Amphiphilic poly(L-amino acids) - new materials for drug delivery. J Control Release 161: 523-36.
43. Hu Q, Gao X, Gu G, Kang T, Tu Y, et al. (2013) Glioma therapy using tumor homing and penetrating peptide-functionalized PEG-PLA nanoparticles loaded with paclitaxel. Biomaterials 2013;34: 5640-50.
44. Guo X, Shi C, Wang J, Di S, Zhou S (2013) pH-triggered intracellular release from actively targeting polymer micelles. Biomaterials 34: 4544-54.
45. Midoux P, Pichon C, Yaouanc JJ, Jaffres PA (2009) Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol 157: 166-78.